At Veranova, we offer end-to-end custom API manufacturing services from our GMP/cGMP-compliant facilities in the US and UK. Our global operations are designed to support pharmaceutical and biotech companies through research, phase I to III clinical trials, and commercial manufacturing.
Collaborate with Veranova
Veranova’s global infrastructure positions us to serve as your primary CDMO partner, from R&D to pilot plant to commercial stage, providing reliable technology transfer and scalable, dependable manufacturing solutions.
With an increasing number of new drugs under development containing highly potent APIs, Veranova is able to combine our extensive technical expertise with specialized equipment in order to produce and handle them safely.
Through our global facilities and GMP-compliant bulk production plants, together with our understanding of the broad regulatory requirements, we have the expertise to ensure the reliable supply of controlled substance APIs.
Veranova specializes in the development and manufacturing of HPAPIs and controlled substances.
Our facilities are engineered with containment capabilities extending up to occupational exposure band (OEB) 5, from research through commercial production. Veranova’s US sites are DEA-licensed for Schedule I-V controlled substances, and our UK facility is licensed by the UK Home Office for Schedules I-IV, helping to ensure secure and compliant handling across the markets we serve. As evidence of our experience and reliability, Veranova holds over 200 active drug master files (DMFs) with controlled substances and specialty APIs.
Our sites have clinical and commercial facilities equipped with a range of reactor systems. The kilo facilities are ideal for producing low-volume, high-complexity and potent APIs, equipped with 5 to 100 L reactors including glass jacketed, glass-lined steel, and Hastelloy.
Our multi-purpose manufacturing plants support scale-up and multi-metric ton manufacturing and are equipped with 100 to 2000 gallon reactors, including glass-lined steel and Hastelloy. Key capabilities include hydrogenation, cryogenics, large scale chromatography, preparative HPLC, tangential flow filtration, and lyophilization.
Veranova’s global infrastructure positions us to serve as your primary CDMO partner, from R&D to pilot plant to commercial stage, providing reliable technology transfer and scalable, dependable manufacturing solutions.
Lab-scale and multipurpose small-scale manufacturing with capacity from 5 L to 2,850 L. cGMP kilo-scale operations to handle highly potent compounds with OEL<0.01µg/m3. Specialized capabilities include hydrogenation and cryogenic capabilities, large-scale chromatography, tangential flow filtration (TFF) and diafiltration, thin film evaporation (TFE), milling, and lyophilization.
Multipurpose small-scale cGMP plants with capacity up to 760 L. Cryogenic capabilities, large-scale chromatography, and thin film evaporation (TFE).
Small- and large-scale cGMP manufacturing with total capacity of 105,000 L. Highly potent compounds with OEL <0.01µg/m3. Specialized capabilities include hydrogenation, Quadro and impact mills, jet mills and micronization.
Multi-purpose small- and large-scale manufacturing. cGMP production of bulk APIs and controlled substances with a total capacity of 60,000 L. Safe handling of highly potent compounds with OEL <0.01µg/m3. Support with hydrogenation, dry milling, and micronization.
Whether you’re developing a new chemical entity or scaling up an established API, Veranova has the expertise and infrastructure to take your product from lab to market with confidence.
Discover new ways to advance your science with Veranova.
Contact us